SCHEMBL13041369

SCHEMBL13041369

CON(C)C(=O)c1ccc(C2(C)OCCO2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.46
CLK1 P49759 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
GPR119 Q8TDV5 5/20 0.36
RXRA P19793 2/20 0.35
RXRB P28702 2/20 0.35
CYP26A1 O43174 2/20 0.35
CYP26B1 Q9NR63 2/20 0.35
OPRM1 P35372 1/20 0.35
OPRL1 P41146 1/20 0.35
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HPGD P15428 1/20 0.34
RXRG P48443 1/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 2/20 0.33
AKT1 P31749 1/20 0.32
AKT2 P31751 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041368 0.78 RAB9A (0.49) ALDH1A1SMN1; SMN2HPGDTSHRMEN1
SCHEMBL5616820 0.77 LMNA (0.43) RXRARXRBCYP26A1CYP26B1SMN1; SMN2
SCHEMBL1012521 0.75 MLYCD (0.57) MLYCDALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL18759164 0.72 CPT1B (0.44) RXRARXRBCYP26A1CYP26B1ALDH1A1
SCHEMBL11827069 0.71 RXRA (0.38) RXRARXRBCYP26A1CYP26B1ALDH1A1
SCHEMBL1303906 0.71 MLYCD (0.57) MLYCDALDH1A1SMN1; SMN2HPGDTSHR
SCHEMBL870352 0.71 MLYCD (0.57) MLYCDALDH1A1SMN1; SMN2HPGDLMNA
SCHEMBL22531823 0.71 MLYCD (0.57) MLYCDRXRAALDH1A1SMN1; SMN2HPGD
SCHEMBL5616831 0.70 L3MBTL1 (0.43) RXRAALDH1A1SMN1; SMN2HPGDLMNA
SCHEMBL14539262 0.70 RXRA (0.37) RXRARXRBCYP26A1CYP26B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765788-B2 Tricyclic inhibitors of hydroxysteroid dehydrogenases AMGEN INC. (US) 2014-07-01 US disclosed
US-8765788-B2 Tricyclic inhibitors of hydroxysteroid dehydrogenases AMGEN INC. (US) 2014-07-01 US disclosed
US-20100280073-A1 TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES AMGEN INC. (US) 2010-11-04 US disclosed
US-20100280073-A1 TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES AMGEN INC. (US) 2010-11-04 US disclosed
WO-2008156601-A1 TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES AMGEN INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280073-A1 TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES HSD11B1, HSD3B1, HSD17B1 MLYCD 832/4885CLK1 3453/4885DYRK1A 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.